Report #2867239

Received Oct 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: PA
Recovered: Unknown
Vaccinated: Jul 19, 2025
Onset: Jul 19, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	946064	IM

Symptoms (2)

Interchange of vaccine productsNo adverse event

Symptom narrative

Had a Dose of Recombivax then a Dose of HEPLISAV-B; Initial report received on 15-Sep-2025. A pharmacist reported that a 40-year-old female received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization after receiving RECOMBIVAX previously. Medical history included a sulfa allergy. No concomitant medications were reported. On 19-Jun-2025, the patient received dose 1 of a hepatitis B vaccine [RECOMBIVAX HB (lot number not available)]. On 19-Jul-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number 946064, expiration date 31-Aug-2027, and NDC number 43528-003-05; site not available)] intramuscularly. No other side effects were reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.

Current illness

Drug allergy (Unknown reaction)

Other medications

Recombivax